Why Moderna Stock Surged Today
Shares of Moderna (NASDAQ: MRNA) rocketed higher on Monday, following bullish analyst commentary and news that the biotech company would be added to a popular stock market index.
As of 2:05 p.m. EDT, Moderna's stock was up more than 20%.
Moderna's experimental COVID-19 vaccine could produce annual sales of more than $5 billion, should it prove both safe and effective. So says Jefferies analyst Michael Yee, who began coverage of Moderna's stock with a buy rating and a $90 target price.
Source Fool.com
